The DOI matches its Crossref record.
Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2
Open accessAbstract
Childhood onset motor neuron diseases or neuronopathies are a clinically heterogeneous group of disorders. A particularly severe subgroup first described in 1894, and subsequently called Brown-Vialetto-Van Laere syndrome, is characterized by progressive pontobulbar palsy, sensorineural hearing loss and respiratory insufficiency. There has been no treatment for this progressive neurodegenerative disorder, which leads to respiratory failure and usually death during childhood. We recently reported the identification of SLC52A2, encoding riboflavin transporter RFVT2, as a new causative gene for Brown-Vialetto-Van Laere syndrome. We used both exome and Sanger sequencing to identify SLC52A2 mutations in patients presenting with cranial neuropathies and sensorimotor neuropathy with or without respiratory insufficiency. We undertook clinical, neurophysiological and biochemical characterization of patients with mutations in SLC52A2, functionally analysed the most prevalent mutations and initiated a regimen of high-dose oral riboflavin. We identified 18 patients from 13 families with compound heterozygous or homozygous mutations in SLC52A2. Affected individuals share a core phenotype of rapidly progressive axonal sensorimotor neuropathy (manifesting with sensory ataxia, severe weakness of the upper limbs and axial muscles with distinctly preserved strength of the lower limbs), hearing loss, optic atrophy and respiratory insufficiency. We demonstrate that SLC52A2 mutations cause reduced riboflavin uptake and reduced riboflavin transporter protein expression, and we report the response to high-dose oral riboflavin therapy in patients with SLC52A2 mutations, including significant and sustained clinical and biochemical improvements in two patients and preliminary clinical response data in 13 patients with associated biochemical improvements in 10 patients. The clinical and biochemical responses of this SLC52A2-specific cohort suggest that riboflavin supplementation can ameliorate the progression of this neurodegenerative condition, particularly when initiated soon after the onset of symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications
Chia, R., Chiò, A., & Traynor, B. J. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30401-5 · Cited by 573
Riboflavin: The Health Benefits of a Forgotten Natural Vitamin
Suwannasom, N., Kao, I., Pruß, A., Georgieva, R., & Bäumler, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030950 · Cited by 444
Riboflavin and health: A review of recent human research
Thakur, K., Tomar, S. K., Singh, A. K., Mandal, S., & Arora, S. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1145104 · Cited by 349
Mitochondrial disease in adults: what's old and what's new?
Chinnery, P. F. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505079 · Cited by 133
Metadata
- Authors
- Foley, A. R., Menezes, M. P., Pandraud, A., Gonzalez, M. A., Al-Odaib, A., Abrams, A. J., Sugano, K., Yonezawa, A., Manzur, A. Y., Burns, J., Hughes, I., McCullagh, B. G., Jungbluth, H., Lim, M. J., Lin, J.-P., Megarbane, A., Urtizberea, J. A., Shah, A. H., Antony, J., Webster, R., Broomfield, A., Ng, J., Mathew, A. A., O’Byrne, J. J., Forman, E., Scoto, M., Prasad, M., O’Brien, K., Olpin, S., Oppenheim, M., Hargreaves, I., Land, J. M., Wang, M. X., Carpenter, K., Horvath, R., Straub, V., Lek, M., Gold, W., Farrell, M. O., Brandner, S., Phadke, R., Matsubara, K., McGarvey, M. L., Scherer, S. S., Baxter, P. S., King, M. D., Clayton, P., Rahman, S., Reilly, M. M., Ouvrier, R. A., Christodoulou, J., Züchner, S., Muntoni, F., & Houlden, H.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-11-15
- Volume
- 137
- Issue
- 1
- Pages
- 44-56
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2107033506
- Cited by
- 188
- References
- 0
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. https://app.cochat.ai/papers/10.1093/brain/awt315
- The paper
- Foley, A. R., Menezes, M. P., Pandraud, A., Gonzalez, M. A., Al-Odaib, A., Abrams, A. J., Sugano, K., Yonezawa, A., Manzur, A. Y., Burns, J., Hughes, I., McCullagh, B. G., Jungbluth, H., Lim, M. J., Lin, J.-P., Megarbane, A., Urtizberea, J. A., Shah, A. H., Antony, J., . . . Houlden, H. (2014). Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain. https://doi.org/10.1093/brain/awt315
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.